In the Kiupel high-grade MCT subset treated with adjunctive therapy, what is the hazard ratio for survival for high Beclin-1 vs low Beclin-1 expression in primary plus recurrent tumors?

• A. 16.3
• B. 1.0
• C. 2.5
• D. 18.9

Answer: (D)

Interpreting hazard ratios from a survival analysis is about understanding how much the risk of death at any moment differs between groups. In this Kiupel high‑grade canine mast cell tumor subset treated with adjunctive therapy, the comparison is between tumors with high Beclin‑1 expression and those with low Beclin‑1 expression, considering both primary and recurrent tumors.

A hazard ratio of 18.9 means that, at any point in time, dogs with high Beclin‑1 expression have about 19 times the hazard of death compared with dogs with low Beclin‑1 expression in this specific context. This indicates a very strong association between elevated Beclin‑1 and poorer survival when adjunctive therapy is used in this subgroup, suggesting autophagy-related biology reflected by Beclin‑1 may influence treatment outcomes.